51 results about "Drug regimen" patented technology

The invention relates to an auxiliary diagnosis and treatment method, device and equipment and a storage medium, and the method comprises the steps: verifying the quality of medical data through an intelligent matching mechanism, and generating a supplementary signal containing standardized guidance for unqualified image data in real time; a cross-modal fusion technology is adopted to integrate the tongue image, the pulse image, the image and the inspection data, and a comprehensive feature vector of a unified dimension is constructed; outputting correlation mapping of the traditional Chinese medicine syndromes and the western medicine diseases based on the pathological reasoning model, and generating a drug treatment scheme and a non-drug treatment scheme through a treatment scheme reasoning model; and finally, dynamically optimizing the dialectical logic parameters and the treatment weight parameters according to user feedback. The method solves the problems of difficulty in multi-source medical data fusion, one-sided diagnosis basis and lack of curative effect feedback closed loop, significantly improves the accuracy and adaptability of personalized diagnosis and treatment, and provides standardized intelligent support for traditional Chinese and western medicine combined diagnosis and treatment.

The invention relates to the technical field of Escherichia coli drug resistance analysis, in particular to an Escherichia coli antibiotic drug resistance detection method based on SERS and machine learning. The invention provides an Escherichia coli antibiotic resistance detection method based on SERS (Surface Enhanced Raman Scattering) and machine learning so as to overcome the defect that high-precision and rapid diagnosis cannot be realized in the prior art. The invention aims to realize rapid and high-precision identification of drug-resistant bacteria through a machine learning algorithm by utilizing a core-shell nanostructure SERS substrate of silver-coated gold nanoparticles and combining SERS spectrum differences of drug-resistant escherichia coli with different phenotypes. Through the method, the detection time can be remarkably shortened, the detection precision can be improved, an accurate drug treatment scheme is provided for clinic, and the method has a wide application prospect.

The invention relates to an application of an intervention SNRK-MTA1 signal channel axis in preparation of a non-small cell lung cancer targeted therapy drug. The nucleotide sequences of the mRNA of the SNRK gene and the mRNA of the MTA1 gene are respectively as shown in SEQ ID NO.1-2. The invention innovatively provides a strategy for treating the non-small cell lung cancer through double-target combined intervention. According to the strategy, SNRK gene expression is improved through exogenous gene overexpression plasmids, and meanwhile MTA1 gene expression is silenced through the siRNA technology. In a non-small cell lung cancer model, the strategy of combined application of the SNRK-OE plasmid and siMTA1 can specifically up-regulate the SNRK mRNA level and knock down the MTA1 mRNA level at the same time, and the combined strategy shows a better anti-tumor effect than single intervention, and can more effectively inhibit the growth and migration of tumor cells. Based on the discovery, the SNRK-MTA1 signal pathway axis can be developed into a novel therapeutic target for non-small cell lung cancer, and is used for designing a drug combination scheme or a composite targeted drug.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The invention relates to a recombinant complement protein and application thereof in preparation of anti-leukemia drugs, and belongs to the technical field of biological medicines. The invention discloses a method for treating acute leukemia by single drug, namely injecting recombinant C1QBP protein, which has a remarkable effect on treating acute leukemia, can be used for remarkably inhibiting proliferation of leukemia cells in marrow, spleen and peripheral blood of a hematopoietic system and also inhibiting infiltration of the leukemia cells in extramedullary organs (skin and the like), so that the whole-body tumor load is reduced, and the curative effect of treating acute leukemia is improved. The lifetime of leukemia mice is obviously prolonged. The recombinant C1QBP protein is combined with a clinical first-line chemotherapy regimen for use, has a synergistic effect, has a stronger effect of inhibiting leukemia cell proliferation compared with a single chemotherapy drug, can significantly prolong the lifetime of leukemia mice, and plays a role in reducing toxicity and enhancing efficacy. The invention proves that the complement C1Q binding protein has the effect of treating leukemia for the first time, provides a preparation method and a drug combination scheme, and has relatively high clinical transformation prospect and application value.

The invention discloses a method and a system for identifying muscular weakness of a critical patient, and relates to the field of muscular weakness identification. Subjective clinical muscular strength grading of the patient and instrument detection data are integrated, a muscular weakness grade mapping model of multiple parts is established, and the diagnosis accuracy is greatly improved; through a host / guest part mapping model, namely in combination with subjective feeling and objective detection data of a patient, the medullary muscular weakness symptom prone to missed diagnosis in traditional examination can be identified; on the basis of a muscle weakness index data prediction mechanism, a muscle weakness crisis risk can be warned in advance; through a treatment-evaluation-adjustment closed-loop system, dynamic optimization of a medicine scheme is realized, the crisis occurrence rate can be greatly reduced, the dosage of an immunosuppressive agent is reduced, meanwhile, the treatment effect is maintained, and the system is suitable for patient groups managed for a long time; by establishing a mapping system of a part type set and an index grade set, quantitative unified evaluation of different types such as eye muscle type / whole body type and the like is realized, and subjective judgment errors are reduced.

The invention relates to the technical field of digital medical treatment and drug evaluation, in particular to an individualized drug curative effect and safety evaluation method and system based on digital twinborn and causal reinforcement learning. Individualized anti-fact prediction is realized through a patient digital twinning model, and potential curative effects and adverse event risks of different medication schemes can be evaluated on a single patient level. Meanwhile, an off-strategy causal reinforcement learning and dual-robust estimation method is adopted, the individualized value of a long-term sequential medication strategy is evaluated from observed real world data, and the preciseness of causal inference is improved; in addition, a curative effect-safety joint value function is constructed, curative effect benefits, safety risks and compliance cost are uniformly incorporated into the same decision framework, and multi-objective joint optimization is achieved; finally, an interpretability analysis report containing key features, value comparison and risk analysis is provided, the understanding and trust of clinicians on recommendation results are enhanced, and application and popularization in clinical practice are facilitated.

The invention discloses a cardiac valve postoperative management method based on cardiac function dynamic monitoring and analysis. A multi-modal dynamic monitoring system is innovatively constructed, a comprehensive sensor array and implantable monitoring equipment are fused, and multi-dimensional data such as electrocardio, blood pressure, myocardial strain and intracardiac pressure are comprehensively collected. A personalized digital heart model is built by means of a deep learning algorithm, a real-time risk assessment and early warning system is formed by combining big data and machine learning, and heart function changes and risks are accurately predicted. According to monitoring and analysis results, a drug treatment scheme is automatically and intelligently adjusted, and a personalized rehabilitation plan covering exercise, diet and psychological guidance is customized. By means of the method, precision and individuation of cardiac valve postoperative management are achieved, data integrity and accuracy are remarkably improved, the complication occurrence rate is effectively reduced, patient compliance is enhanced, and patient rehabilitation is powerfully promoted.

In particular, this disclosure provides technologies, including I-66 formulations, compositions, and methods, for treating various cancers. This disclosure provides technologies, such as formulations, dosages, and drug regimens, for treating conditions, disorders, or diseases, in particular certain types of cancer. In some embodiments, this disclosure provides high-purity I-66 active pharmaceutical ingredients. In some embodiments, this disclosure provides I-66 pharmaceutical products. In some embodiments, this disclosure provides I-66 formulations, which are liquid compositions in which I-66 has sufficiently high solubility and stability for clinical application.

To provide dosing regimens of GLP-1 analogs for the treatment of fat, obese, overweight, nonalcoholic fatty liver disease (NAFLD), and / or nonalcoholic steatohepatitis (NASH).SOLUTION: Administering to the subject a first effective amount of one or more first active ingredients selected from the group consisting of GLP-1 and GLP-1 analogs; A dosing regimen is provided, comprising: a first effective amount administered continuously, or intermittently at an interval between two consecutive administrations of six hours or less; and one or more second active ingredients selected from the group consisting of a second effective amount of GLP-I and a GLP-1 analog, administered to said subject once daily, twice daily, three times daily, or four times daily.SELECTED DRAWING: None

The present application relates to the technical field of digital medicine and drug evaluation, and particularly relates to an individualized drug efficacy and safety evaluation method and system based on digital twinning and causal reinforcement learning. Through a patient digital twinning model, individualized counterfactual prediction is realized, which can evaluate the potential efficacy and adverse event risk of different drug regimens at the individual patient level. Meanwhile, off-policy causal reinforcement learning and double robust estimation methods are used to evaluate the individualized value of long-term sequential drug strategies from observational real-world data, improving the rigor of causal inference. In addition, a combined efficacy-safety value function is constructed, which unifies efficacy benefits, safety risks, and compliance costs into the same decision framework, enabling multi-objective joint optimization. Finally, an interpretable analysis report is provided, including key features, value comparisons, and risk analyses, which enhances clinicians' understanding and trust in the recommended results, facilitating the application in clinical practice.

Disclosed are a system, techniques and processes for monitoring and modifying a drug treatment regimen when a user partakes in a ketogenic diet. The disclosed system obtains ketone level measurements of a user and indicates a user's adherence to the ketogenic diet as well as modifying a user's total daily dosage of a drug based on the user's following the ketogenic diet.

A computer-implemented system for recording, tracking and reporting administration of one or more pharmaceutical treatment regimens, the system including one or more databases wherein details of one or more pharmaceutical treatment regimens are recorded, the databases accessible by processors associated with a first user device having access to the databases by a data communications network, the processors executing instructions that notify a first user, using the first user device, of details of a pharmaceutical treatment regimen associated with the first or second user, record details a pharmaceutical administration in accordance with treatment regimen entered by the first user using the first user device, and non-adherence to the treatment regimen by the first user, automatically notify another user, using a second user device wherein the another user has database access by the data communications network, of the non-adherence to treatment regimen by the first user.

The invention provides a patient closed-loop management system and method based on drug-treatment scheme risk stratification, and relates to the technical field of medical monitoring, and the system comprises a monitoring data module which is used for obtaining medical environment data, body movement data, sleep data and core body health data through an intelligent medical terminal and a sensor; the user data module is used for acquiring historical medical data, basic data and historical monitoring data of the user; the sleep health module is used for determining a sleep health coefficient according to the user historical monitoring data, the user basic data, the historical medical data and the sleep data; the body health module is used for determining a body health coefficient according to the body movement data and the core body health data; the environment safety module is used for determining a medical environment safety coefficient according to the medical environment data; and the monitoring report module is used for determining a monitoring report. According to the invention, comprehensiveness and accuracy of patient closed-loop management can be improved.

The present application relates to the technical field of drug management, and discloses a kind of chronic kidney disease patient whole-course drug therapy wisdom management method and system, comprising: obtaining the electronic medical record of patient by the personal information of patient;Initial drug regimen is obtained based on electronic medical record and sent to medication decision unit, and final drug regimen is obtained based on medication decision unit, after confirming that drug code and drug quantity are consistent with drug code and drug quantity in final drug regimen, unit warehouse hash value is obtained using drug code, drug quantity and medication decision unit, drug reminder is generated according to final drug regimen, medication record is obtained using patient use port, and reconsultation reminder is obtained according to medication record, after sending the reconsultation reminder to patient use port and data storage unit, complete chronic kidney disease drug whole-process management.The present application can complete the drug management of chronic kidney disease patient and track medicine.

The invention provides a medical supervision platform. A patient personal information base and a pathology big database are established; the doctor inquires the patient according to the information of the patient information base and makes corresponding diagnosis; the supervision module compares and checks the diagnosis content of the proofreading doctor through big data; after checking, doctor diagnosis is input into a patient information base, and corresponding medical resources are allocated; the patient personal information base comprises basic information of patients, past medical history, medicine allergy history, examination results and uncomfortable symptoms, the pathology big database comprises disease names, disease indications, medicine principles and treatment modes, the platform can improve the accuracy and rationality of medical diagnosis, and by checking a medicine treatment scheme of a doctor, the medical diagnosis accuracy and rationality can be improved. And the treatment mode, the medicine type and the dosage are ensured to meet medical standards and patient requirements. The proofreading steps are helpful for reducing the risk of drug treatment and improving the treatment effect of patients.

A mesh network medication coordination system enables communication between intelligent injection devices, monitoring systems, patient devices, or healthcare provider devices to prevent adverse drug interactions in hospital settings. The system includes mesh network infrastructure supporting multiple networked devices, dosage measurement devices that directly measure or infer dosage administration including injection completion detection, medication volume measurement, administration timing data, or patient biometric responses, or a coordination module that coordinates medication administration timing across multiple devices. The system features drug interaction analysis capabilities, real-time monitoring of patient vital signs and medication effectiveness, alert generation for potential interactions and dosing conflicts, or data synchronization across all networked devices. This integrated approach optimizes dosing intervals, prevents conflicting medication schedules, synchronizes administration events, or maintains consistent medication administration data across the mesh network to enhance patient safety and treatment efficacy.

A method for developing novel drug therapies utilizing properties of existing drug therapies, the method comprising the steps of: developing a novel therapeutic mathematical model of a target biological network and synthesizing a drug therapy based on the novel therapeutic mathematical model. The novel therapeutic mathematical model is capable of generating novel therapeutic time-course progressions, which include time-course progression features found in existing therapeutic time-course progressions of existing therapeutic mathematical models of the target biological network. The time-course progression features can be correlated with the outcomes of the target biological network. Each new therapeutic intervention constant can be used to synthesize a drug regimen, and these drug regimens collectively constitute the novel drug therapy.

The invention relates to the technical field of information retrieval, in particular to an information retrieval method, a medium and equipment, which support the retrieval of three types of keywords, integrate multiple types of nodes in a graph, pre-construct a material relationship knowledge graph containing multi-dimensional nodes and association relationships, and combine visual output of a material information table and an association sub-graph, so that the information retrieval efficiency is improved. A logic chain between the medicine and each associated element is visually displayed, and associated query requirements of a user in multiple scenes can be met without cross-platform multiple retrieval; according to the method, authoritative data are integrated in the atlas construction process, so that association of drugs, treatment schemes and diseases has clinical reasonability and authority, meanwhile, association sub-atlases are extracted through association extension, false association and irrelevant information are effectively filtered, and the accuracy and reliability of retrieval results are improved; by outputting the first retrieval result page and the second retrieval result page in stages, the requirement of a user for rapidly screening target substances is met, deep detailed information can be provided, and the retrieval efficiency and the information depth are balanced.

The invention discloses an application of glutathione peroxidase 3 as a therapeutic target in preparation of a medicine for treating pulmonary fibrosis, and an application of a compound Ebselen in preparation of a medicine for treating pulmonary fibrosis. Through single cell and space transcriptomics analysis, it is found for the first time that expression of GPX3 in pulmonary fibrosis patients and model animal lung tissues is significantly reduced. In-vivo and in-vitro experiments prove that up-regulation of GPX3 expression can effectively inhibit fibroblast activation, migration, proliferation and oxidative stress and block a TGF-beta1 / Smad signal channel, so that collagen deposition and pulmonary fibrosis pathological change are relieved. Furthermore, a GPX3 simulant Ebselen is given by adopting an aerosol inhalation mode, is preferably loaded in liposome, and shows a remarkable anti-fibrosis effect in two mouse pulmonary fibrosis models induced by bleomycin and silicon dioxide. The invention provides a brand-new therapeutic target and a medicine scheme with clinical transformation potential for pulmonary fibrosis.

Computer-implemented methods and systems for managing the collection of and access to behavior assessment data. In an embodiment, a first user having authority to act on behalf of an individual under study identifies a second and third user role, specifies behavior data, symptom measurement data, and / or medicine regimen data associated with the individual under study, and defines access permissions for the second and third user roles with respect to the behavior data and symptom measurement data. The symptoms and behaviors to be measured are specified based on a condition of the individual. Users provide behavior data and symptom measurement data observed from the individual. An analytics module performs computational analysis on the behavior data and symptom measurement data, thereby producing behavior assessment data. A reporting module presents the behavior assessment data to the users in a manner consistent with the defined access permissions.

This invention relates to the pharmaceutical field, and more specifically to a drug used for the treatment of locally advanced, unresectable or metastatic colorectal cancer, and its use. Compared to a two-drug regimen of cintirimab + tucidinostat, the tripartite regimen of cintirimab + tucidinostat + IBI305 provided by this invention can significantly extend progression-free survival in patients with MSS / MSI-L locally advanced, unresectable or metastatic colorectal cancer. Furthermore, in terms of indicators such as ORR, PR, PD, NE, and DCR, patients with MSS / MSI-L locally advanced, unresectable or metastatic colorectal cancer can obtain significant benefits from the tripartite regimen of cintirimab + tucidinostat + IBI305.

The invention discloses an antisense oligonucleotide medicine for treating pituitary tumor. According to evidence of molecular biology experiments and the like and verification in human primary pituitary tumor cells, the designed specific ASO medicine is applied to treatment of pituitary tumors for the first time. The ASO drug inhibits the expression of MDM2, recovers the activity of P53 protein, inhibits the proliferation of pituitary tumors and promotes apoptosis by inhibiting the splicing process mediated by a splicing factor FUS, and provides a new direction for a potential medication scheme for pituitary tumor treatment.

A method for aiding the detection of drug effect using anaesthesia-induced patterns in an electroencephalogram (EEG), comprising: obtaining EEG data corresponding to one or more EEG signals of a patient under general anaesthesia measured using an EEG, wherein the one or more EEG signals are time-varying and comprise a time series of segments comprising at least a repeating first segment type and a repeating second segment type, wherein instances of segments corresponding to the first segment type alternate with instances of segments corresponding to the second segment type; and determining a signal metric comprising a series of time ordered metric datapoints, wherein each metric data point is determined based on: a comparison between at least two segments temporally associated with the metric point; and / or a comparison between at least two different measures of at least one segment temporally associated with the metric point, wherein the signal metric is a measurement of an effect of an anaesthetic drug regimen administered to the patient, and related methods and systems.

Multi-drug resistant tuberculosis (TB) is a major public health problem concerning about half a million cases each year. Patients hardly adhere to the current strict treatment consisting of more than 10,000 tablets over a 2-year period. There is a clear need for efficient and better-formulated medications. The inventors have previously shown that nanoparticles made of cross-linked poly-β-cyclodextrins (pβCD) are efficient vehicles for pulmonary delivery of powerful combinations of anti-TB drugs. Here, they report that in addition to be efficient drug carriers, pβCD nanoparticles are endowed with intrinsic antibacterial properties. Indeed, empty pβCD are able to impair M. tuberculosis (Mtb) establishment after pulmonary administration in mice. pβCD hamper colonisation of macrophages by Mtb by interfering with lipid rafts, without inducing toxicity. Moreover, pβCD provoke macrophage apoptosis leading to depletion of infected cells, thus creating a lung micro-environment detrimental to Mtb persistence. Taken together, the results suggest that materials made of cross-linked β-cyclodextrins (e.g. nanoparticles) loaded or not with antibiotics play an antibacterial action by its own and could be used as carrier in drug regimen formulations effective against TB.

To provide a therapeutic method for the treatment of small cell lung cancer (SCLC).SOLUTION: A method for treating Delta-like 3 (DLL3)-positive cancer comprises administering to a subject in need thereof an anti-DLL3 agent at a dose of 3 mg to 200 mg once every two weeks.SELECTED DRAWING: None

The present application relates to the technical field of escherichia coli drug resistance analysis, and particularly relates to a detection method for escherichia coli antibiotic resistance based on SERS and machine learning. The present application provides a detection method for escherichia coli antibiotic resistance based on SERS and machine learning to overcome the defects that high-precision and rapid diagnosis cannot be achieved in the prior art. The present application aims to utilize the core-shell nanostructure SERS substrate of silver-coated gold nanoparticles, combine the SERS spectrum differences of different phenotypic drug-resistant escherichia coli, and realize rapid and high-precision drug-resistant bacteria identification through machine learning algorithms. Through this method, the detection time can be significantly shortened, the detection accuracy can be improved, and accurate drug treatment plans can be provided for the clinic, which has a wide application prospect.

The application discloses a urology use split type urine collecting bag, which comprises a first urine collecting area, a second urine collecting area, a third urine collecting area and a fourth urine collecting area, a first tearable strip is arranged between the first urine collecting area and the second urine collecting area and the fourth urine collecting area, a second tearable strip is arranged between the third urine collecting area and the second urine collecting area and the fourth urine collecting area, the first tearable strip and the second tearable strip are gathered and connected to a center point of the urine collecting bag, an adjusting part is detachably connected to an outer wall surface of the urine collecting bag, the adjusting part comprises a disc and a rotating motor embedded in the center of the disc, an adjusting fixing piece is connected to an output end of the rotating motor, and the adjusting fixing piece is respectively in contact with the first urine collecting area, the second urine collecting area, the third urine collecting area and the fourth urine collecting area, so as to adjust the positions of the first urine collecting area, the second urine collecting area, the third urine collecting area and the forth urine collecting area. The application is convenient for observing the urine volume of a patient and formulating a drug treatment scheme suitable for the individual, and effectively avoids the problems of poor experience of the patient and waste of medical resources caused by replacing the urine collecting bag due to multiple times of taking and placing urine.

The present application provides a set of complete innovative technical solutions from target discovery to treatment intervention for the immune escape and drug resistance recurrence problems existing in the clinical treatment of multiple myeloma (MM). It is found that Siglec7 is mainly highly expressed on the surface of NK cells, and the proportion and expression intensity of Siglec7 positive NK cells are significantly higher than those of complete remission and non-tumor controls; further, Siglec7 monoclonal antibody is prepared, and when the anti-Siglec7+CD38 monoclonal antibody (such as daratumumab) is used, a significant synergistic anti-tumor effect can be produced in vitro and in vivo. The technical solution completely constructs the research and development chain of "marker discovery-target verification-drug development-treatment application", and provides a new target, specific antibody drug and innovative combined drug regimen for the precise diagnosis, prognosis and especially immunotherapy of refractory and relapsed patients with multiple myeloma, which has great clinical transformation value and market prospect.